Clinical Trial

A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes

Study acronym: CARAT
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study will compare the effect and safety of cofrogliptin (HSK7653) with acarbose among people with type 2 diabetes
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-07.
Trial Details
NCT Number NCT07122102
Lead Sponsor Haisco Pharmaceutical Group Co., Ltd.
Conditions Type 2 Diabetes
Enrollment 200 participants
Start Date 2025-10-01
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-26